Dick C Chan1, Minh N Nguyen, Gerald F Watts, P Hugh R Barrett. 1. Metabolic Research Centre, School of Medicine and Pharmacology, University of Western Australia, Royal Perth Hospital, GPO Box X2213, Perth, Western Australia 6847, Australia.
Abstract
CONTEXT: Apolipoprotein (apo) C-III is associated with hypertriglyceridemia and progression of cardiovascular disease. Plasma apoC-III is elevated in centrally obese men, and we hypothesized that the kinetics of apoC-III are disturbed in these subjects. OBJECTIVE: We developed a compartmental model to determine very low-density lipoprotein (VLDL) and high-density lipoprotein (HDL) apoC-III metabolic parameters in centrally obese men and investigated the associations with VLDL-apoB and HDL-apoA-I kinetics. STUDY DESIGN: Apolipoprotein kinetics was determined using stable isotope techniques and compartmental modelling in 39 centrally obese and 12 nonobese men. RESULTS: Compared with nonobese subjects, centrally obese subjects had increased plasma apoC-III concentration (160 +/- 5 mg/liter vs. 103 +/- 9 mg/liter, P < 0.001), reflecting increased concentrations of both VLDL-apoC-III and HDL-apoC-III. These related to increased production rate (PR) of VLDL-apoC-III (2.12 +/- 0.14 vs. 1.56 +/- 0.29 mg/kg x d, P < 0.05) and reduced fractional catabolic rate (FCR) of both VLDL- and HDL-apoC-III (0.70 +/- 0.02 pools/d vs. 0.82 +/- 0.05 pools/d, P < 0.05). In centrally obese men, VLDL-apoC-III concentration was significantly (P < 0.05) associated with VLDL-apoB concentration and PR as well as HDL-apoA-I FCR and PR and inversely with VLDL-apoB FCR. HDL-apoC-III concentration was significantly (P < 0.05) associated with the concentrations of both VLDL-apoB and HDL-apoA-I, the FCR, and the PR of HDL-apoA-I and inversely with the VLDL-apoB FCR. In multiple regression analysis, both VLDL-apoC-III and HDL-apoC-III concentrations were significantly associated with HDL-apoA-I FCR. CONCLUSIONS: In centrally obese men, elevated VLDL-apoC-III and HDL-apoC-III concentrations are a consequence of elevated production and decreased catabolism of VLDL-apoC-III and reduced catabolism of HDL-apoC-III, respectively. These defects are associated with disturbances in VLDL-apoB and HDL-apoA-I metabolism.
CONTEXT: Apolipoprotein (apo) C-III is associated with hypertriglyceridemia and progression of cardiovascular disease. Plasma apoC-III is elevated in centrally obesemen, and we hypothesized that the kinetics of apoC-III are disturbed in these subjects. OBJECTIVE: We developed a compartmental model to determine very low-density lipoprotein (VLDL) and high-density lipoprotein (HDL) apoC-III metabolic parameters in centrally obesemen and investigated the associations with VLDL-apoB and HDL-apoA-I kinetics. STUDY DESIGN: Apolipoprotein kinetics was determined using stable isotope techniques and compartmental modelling in 39 centrally obese and 12 nonobese men. RESULTS: Compared with nonobese subjects, centrally obese subjects had increased plasma apoC-III concentration (160 +/- 5 mg/liter vs. 103 +/- 9 mg/liter, P < 0.001), reflecting increased concentrations of both VLDL-apoC-III and HDL-apoC-III. These related to increased production rate (PR) of VLDL-apoC-III (2.12 +/- 0.14 vs. 1.56 +/- 0.29 mg/kg x d, P < 0.05) and reduced fractional catabolic rate (FCR) of both VLDL- and HDL-apoC-III (0.70 +/- 0.02 pools/d vs. 0.82 +/- 0.05 pools/d, P < 0.05). In centrally obesemen, VLDL-apoC-III concentration was significantly (P < 0.05) associated with VLDL-apoB concentration and PR as well as HDL-apoA-I FCR and PR and inversely with VLDL-apoB FCR. HDL-apoC-III concentration was significantly (P < 0.05) associated with the concentrations of both VLDL-apoB and HDL-apoA-I, the FCR, and the PR of HDL-apoA-I and inversely with the VLDL-apoB FCR. In multiple regression analysis, both VLDL-apoC-III and HDL-apoC-III concentrations were significantly associated with HDL-apoA-I FCR. CONCLUSIONS: In centrally obesemen, elevated VLDL-apoC-III and HDL-apoC-III concentrations are a consequence of elevated production and decreased catabolism of VLDL-apoC-III and reduced catabolism of HDL-apoC-III, respectively. These defects are associated with disturbances in VLDL-apoB and HDL-apoA-I metabolism.
Authors: Shirya Rashid; P Hugh R Barrett; Kristine D Uffelman; Takehiko Watanabe; Khosrow Adeli; Gary F Lewis Journal: Arterioscler Thromb Vasc Biol Date: 2002-03-01 Impact factor: 8.311
Authors: F M Sacks; P Alaupovic; L A Moye; T G Cole; B Sussex; M J Stampfer; M A Pfeffer; E Braunwald Journal: Circulation Date: 2000-10-17 Impact factor: 29.690
Authors: Gerald F Watts; P Hugh R Barrett; Juying Ji; Adrian P Serone; Dick C Chan; Kevin D Croft; Franziska Loehrer; Anthony G Johnson Journal: Diabetes Date: 2003-03 Impact factor: 9.461
Authors: Dick C Chan; Gerald F Watts; P Hugh R Barrett; Lawrence J Beilin; Trevor G Redgrave; Trevor A Mori Journal: Diabetes Date: 2002-08 Impact factor: 9.461
Authors: Jeffrey S Cohn; Bruce W Patterson; Kris D Uffelman; Jean Davignon; George Steiner Journal: J Clin Endocrinol Metab Date: 2004-08 Impact factor: 5.958
Authors: Andrea Kassai; Ranganath Muniyappa; Amy E Levenson; Mary F Walter; Brent S Abel; Michael Ring; Simeon I Taylor; Sudha B Biddinger; Monica C Skarulis; Phillip Gorden; Rebecca J Brown Journal: J Clin Endocrinol Metab Date: 2016-02-22 Impact factor: 5.958
Authors: Karin Åvall; Yusuf Ali; Ingo B Leibiger; Barbara Leibiger; Tilo Moede; Meike Paschen; Andrea Dicker; Elisabetta Daré; Martin Köhler; Erwin Ilegems; Midhat H Abdulreda; Mark Graham; Rosanne M Crooke; Vanessa S Y Tay; Essam Refai; Stefan K Nilsson; Stefan Jacob; Lars Selander; Per-Olof Berggren; Lisa Juntti-Berggren Journal: Proc Natl Acad Sci U S A Date: 2015-05-04 Impact factor: 11.205
Authors: Toni I Pollin; Coleen M Damcott; Haiqing Shen; Sandra H Ott; John Shelton; Richard B Horenstein; Wendy Post; John C McLenithan; Lawrence F Bielak; Patricia A Peyser; Braxton D Mitchell; Michael Miller; Jeffrey R O'Connell; Alan R Shuldiner Journal: Science Date: 2008-12-12 Impact factor: 47.728
Authors: Dick C Chan; Gerald F Watts; Esther M M Ooi; Juying Ji; Anthony G Johnson; P Hugh R Barrett Journal: Arterioscler Thromb Vasc Biol Date: 2008-06-19 Impact factor: 8.311
Authors: Beatriz Talayero; Liyun Wang; Jeremy Furtado; Vincent J Carey; George A Bray; Frank M Sacks Journal: J Lipid Res Date: 2014-06-25 Impact factor: 5.922
Authors: Meenakshi Sundaram; Shumei Zhong; Maroun Bou Khalil; Philip H Links; Yang Zhao; Jahangir Iqbal; M Mahmood Hussain; Robin J Parks; Yuwei Wang; Zemin Yao Journal: J Lipid Res Date: 2010-01 Impact factor: 5.922
Authors: Meenakshi Sundaram; Shumei Zhong; Maroun Bou Khalil; Hu Zhou; Zhenghui G Jiang; Yang Zhao; Jahangir Iqbal; M Mahmood Hussain; Daniel Figeys; Yuwei Wang; Zemin Yao Journal: J Lipid Res Date: 2010-01-23 Impact factor: 5.922